Read ALEARDL_634354565693777530 text version

Clinical Trial Coordinators Jennifer Black: [email protected] Jessica Borras: [email protected] Telephone: 02380 795302 Fax: 02380 794020

University of Southampton Clinical Trials Unit MP 131, Southampton General Hospital Tremona Road Southampton Hampshire SO16 6YD

Form completed : Form completed by : Form completion date: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Randomisation form Vergis 11-3-2011 at 16:9:8 yes yes yes yes no no no no no no no no no no no no no 12 1 = high

Aged 18 years or older Clinical Alcoholic Hepatitis: Less than 4 weeks since admission to hospital DF* greater than or equal to 32 Abstinence of >6 weeks prior to randomisation Duration of jaundice > 3 months Other causes of liver disease including: Evidence of current malignancy (except non-melanotic skin cancer) Previous entry into the study, or use of either prednisolone or PTX within 6 months. AST >500 or ALT >300 (not compatible with alcoholic hepatitis) Patients with a serum creatinine >500 µmol/L or requiring renal support Patients dependent upon inotropic support (adrenaline or noradrenaline). Active gastro-intestinal haemorrhage Untreated sepsis Patients with known hypersensitivity to pentoxifylline, other methyl xanthines, or any of the excipients Patients with cerebral haemorrhage, extensive retinal haemorrhage, acute myocardial infarction (within the last 6 weeks) Pregnant or lactating women. Institute is Stand alone, or associated with HUB Risk*

Patient has been assigned patient number: 102-5001 Allocated patient pack: 0077 For enquiries please contact your Clinical Trial Coordinator at UoSCTU.

Randomization service provided by TENALEA - www.tenalea.com

Information

ALEARDL_634354565693777530

1 pages

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate

1071579


You might also be interested in

BETA
ALEARDL_634354565693777530